Skip to content

Moyamoya Disease 2 C1846689

Published: July 22, 2026Updated: August 25, 2026

A genetic form of Moyamoya disease where brain blood vessels progressively narrow, affecting blood supply to the brain. It can develop in childhood or adulthood and may lead to stroke. Surgical procedures can help improve brain circulation.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 25, 2026Editorial policy

Key facts at a glance

ICD-10
G40.909
ICD-11
8A00.0
Body system
neurologic
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Transient ischemic attacks (TIA)

!

Ischemic stroke

!

Seizures

Generalized symptoms

(neurologic)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Headache

(neurologic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Cerebral revascularization procedures

Surgical revascularization through direct bypass, indirect bypass, or combined approaches to restore perfusion to affected brain regions and prevent ischemic complications.

surgical
2

Combination drug regimen with regular assessment

Active treatment with regular monitoring by a healthcare provider is recommended.

medication

Additional treatment options

Advanced cerebrovascular monitoring

Quantitative imaging including perfusion studies and vasoreactivity testing to assess hemodynamic reserve and determine optimal timing for surgical intervention.

monitoring

Vasodilator and antiplatelet therapy

Pharmacological management using vasodilators to improve cerebral blood flow and antiplatelet agents to reduce thrombotic risk in Moyamoya disease.

medication

Neurocognitive support

Neuropsychological evaluation and cognitive rehabilitation for patients experiencing cognitive decline, attention deficits, or memory issues related to cerebrovascular compromise.

psychological

Risk factor management and activity modification

Comprehensive lifestyle modifications including avoidance of dehydrating conditions, extreme temperatures, and high-risk activities that may precipitate ischemic events.

lifestyle

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Moyamoya Disease 2 C1846689?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Medication Comparisons

Compare medications used to treat Moyamoya Disease 2 C1846689. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy